Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 3/20 | 0.37 |
| ▸ | CYP26B1 | Q9NR63 | 3/20 | 0.37 |
| ▸ | RXRA | P19793 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7684750 | 0.78 | CYP26A1 (0.49) | CYP26A1CYP26B1RXRAIDH1RXRB | |
| SCHEMBL7548006 | 0.73 | CYP26A1 (0.45) | CYP26A1CYP26B1RXRARXRB | |
| SCHEMBL7684752 | 0.66 | CYP26A1 (0.55) | CYP26A1CYP26B1RXRA | |
| SCHEMBL5738022 | 0.66 | CYP26A1 (0.41) | CYP26A1CYP26B1 | |
| SCHEMBL5736370 | 0.66 | CYP26A1 (0.50) | CYP26A1CYP26B1 | |
| SCHEMBL5520361 | 0.65 | AGBL2 (0.52) | RXRAPTGS1PTGS2IDH1 | |
| SCHEMBL1415211 | 0.63 | AGBL2 (0.43) | CYP26A1CYP26B1PTGS1PTGS2 | |
| SCHEMBL18832186 | 0.61 | PANK3 (0.49) | — | |
| SCHEMBL2599712 | 0.61 | PTGS2 (0.36) | PTGS1PTGS2 | |
| SCHEMBL13614076 | 0.58 | CYP26A1 (0.43) | CYP26A1CYP26B1RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6359135-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2002-03-19 | — | — | US | disclosed |